Actelion Ltd. News Conference As Drugmaker Agrees $30 Takeover Billion With Johnson & Johnson
Joaquin Duato, executive vice president at Johnson & Johnson, speaks during a news conference to announce Johnson & Johnson takeover of Actelion Ltd., at the Actelion headquarter offices in Allschwil, Switzerland, on Thursday, Jan. 26, 2017. Johnson & Johnson agreed to buy Actelion for $30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines for a rare type of high blood pressure. Photographer: Michele Limina/Bloomberg via Getty Images
PURCHASE A LICENSE
How can I use this image?
kr. 2.200,00
DKK
Getty ImagesActelion Ltd. News Conference As Drugmaker Agrees $30 Takeover..., News Photo
Actelion Ltd. News Conference As Drugmaker Agrees $30 Takeover... Get premium, high resolution news photos at Getty ImagesProduct #:632761610
Actelion Ltd. News Conference As Drugmaker Agrees $30 Takeover... Get premium, high resolution news photos at Getty ImagesProduct #:632761610kr.3.000kr.850
Getty Images
In stockDETAILS
Restrictions:
Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credit:
Editorial #:
632761610
Collection:
Bloomberg
Date created:
January 26, 2017
Upload date:
License type:
Release info:
Not released. More information
Source:
Bloomberg
Object name:
SWITZERLAND ACTELION
Max file size:
4000 x 2667 px (13.33 x 8.89 in) - 300 dpi - 4 MB